# Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis

> **NCT01201356** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 4125 (actual)

## Conditions studied

- Relapsing Forms of Multiple Sclerosis

## Interventions

- **DRUG:** Fingolimod

## Key facts

- **NCT ID:** NCT01201356
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09-13
- **Primary completion:** 2018-10-19
- **Final completion:** 2018-10-19
- **Target enrollment:** 4125 (ACTUAL)
- **Last updated:** 2021-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01201356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01201356, "Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01201356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*